IQVIA Research: The Link Between Digital Engagement and Therapy Persistence

Keeping patients on therapy is critical to achieving better outcomes, yet many pharmaceutical organizations still struggle to influence persistence at scale. As investment in digital patient support continues to grow, organizations need evidence that these programs deliver measurable results.

An IQVIA study conducted with Medisafe demonstrated a significant improvement in therapy persistence among chronically nonadherent patients who used the Digital Drug Companion. Across hypertension, depression, and diabetes populations, patients using the platform remained on therapy substantially longer than matched controls.

The Digital Drug Companion Advantage

Across hypertension, depression, and diabetes populations, several key themes emerged:

• Digital Drug Companion users achieved 69.3% persistence at month 12, compared to 30% for matched controls.
• The persistence gap between users and non-users continued to widen over time.
• Results were consistent across multiple chronic disease categories.
• The greatest impact was observed among chronically non-adherent patients.

These findings demonstrate the potential for digital engagement to improve long-term therapy continuation among patient populations most at risk of discontinuation.

How Digital Support Influences Behavior

The study reinforces a shift in how pharmaceutical organizations approach patient support. Patients spend only a fraction of their treatment journey interacting with healthcare providers, creating significant gaps between care touchpoints. 

Rather than relying solely on education or reminders, the Digital Drug Companion delivers ongoing engagement, medication management, and personalized support throughout the treatment journey. By integrating into daily life, the platform helps drive behavioral change, strengthen treatment habits, and support long-term therapy persistence.

The Right Partner for Digital Engagement

Built on 12+ years of real-world patient behavior data, Medisafe helps pharmaceutical organizations improve therapy persistence through personalized digital engagement.

By combining medication management, behavioral intelligence, and patient support tools, Medisafe enables brands to deliver more connected experiences throughout the treatment journey.

The result is stronger persistence, improved patient engagement, and better long-term outcomes.

New Insights Into Therapy Persistence

Medisafe's latest research with IQVIA explores the measurable impact of the Digital Drug Companion on therapy persistence among chronically non-adherent patients.

The findings provide new evidence on how personalized digital engagement can improve treatment continuation across chronic disease populations.

‍